Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.
In light of the opioid epidemic within the United States, Dr. Eric Gross and colleagues developed a non-opioid therapeutic that reduces pain (Stanford Medicine Press Release).